ANI Pharmaceuticals Inc. has announced its financial guidance for 2026, projecting total net revenues between $1,055 million and $1,115 million. The company expects its Rare Disease business to account for approximately 60% of total net revenues, with Cortrophin Gel net revenues forecasted at $540 million to $575 million. Adjusted non-GAAP EBITDA is anticipated to range from $275 million to $290 million for the year. This outlook follows significant growth in 2025, where total net revenues increased by at least 39% and adjusted non-GAAP EBITDA grew by at least 42%. The Rare Disease segment delivered strong results in 2025, highlighted by a 76% year-over-year increase in Purified Cortrophin® Gel net revenues, reaching $347.8 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ANI Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9623607-en) on January 12, 2026, and is solely responsible for the information contained therein.